Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: Biomaterials. 2013 Oct 5;35(1):269–277. doi: 10.1016/j.biomaterials.2013.09.050

Figure 2.

Figure 2

Specific CD8+ T cell proliferation in response to specified aAPC dose, protein density, and shape of aAPC. (A) CFSE dilution data for ellipsoidal (red) and spherical aAPC (black) at the highest protein dose (0.75 μg dimer/mg PLGA) at 3 doses of aAPC (0.01 mg, 0.1mg, and 1mg/105 CD8+ pmel CD8+ T cells) compared to non-cognate. (B) CD8+ T cell proliferation (fold expansion/105 cells) 7 days after aAPC addition to T cells with indicated doses, shapes (ellipsoidal in red, spherical in white), and protein densities. (For comparison of ellipsoid vs. spherical, * p<0.05, **p<0.01, ***p<0.001; n=3). (C) CD8+ T cell proliferation (fold expansion/105 cells) versus total MHC-dimer dose (in μg) for ellipsoidal (red) and spherical (black) aAPCs. (D) CD8+ T cell proliferation (fold expansion/105 cells) versus MHC-dimer density (in MHC-Ig/μm2) for ellipsoidal (red) and spherical (black) aAPC at 3 doses of aAPC (0.01 mg, 0.1mg, and 1mg/105 CD8+ pmel CD8+ T cells).